JP2015533366A - 改良されたヒトヘルペスウイルス免疫療法 - Google Patents

改良されたヒトヘルペスウイルス免疫療法 Download PDF

Info

Publication number
JP2015533366A
JP2015533366A JP2015537084A JP2015537084A JP2015533366A JP 2015533366 A JP2015533366 A JP 2015533366A JP 2015537084 A JP2015537084 A JP 2015537084A JP 2015537084 A JP2015537084 A JP 2015537084A JP 2015533366 A JP2015533366 A JP 2015533366A
Authority
JP
Japan
Prior art keywords
cmv
protein
amino acid
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015537084A
Other languages
English (en)
Japanese (ja)
Inventor
カンナー、ラジブ
ビジェイエンドラ、ダサリ
Original Assignee
ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904604A external-priority patent/AU2012904604A0/en
Application filed by ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ filed Critical ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ
Publication of JP2015533366A publication Critical patent/JP2015533366A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015537084A 2012-10-19 2013-10-21 改良されたヒトヘルペスウイルス免疫療法 Pending JP2015533366A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012904604 2012-10-19
AU2012904604A AU2012904604A0 (en) 2012-10-19 Improved human cytomegalovirus immunotherapy protein
PCT/AU2013/001216 WO2014059489A1 (en) 2012-10-19 2013-10-21 Improved human herpesvirus immunotherapy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018010690A Division JP2018075034A (ja) 2012-10-19 2018-01-25 改良されたヒトヘルペスウイルス免疫療法
JP2018207238A Division JP6846396B2 (ja) 2012-10-19 2018-11-02 改良されたヒトヘルペスウイルス免疫療法用タンパク質

Publications (1)

Publication Number Publication Date
JP2015533366A true JP2015533366A (ja) 2015-11-24

Family

ID=50487350

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015537084A Pending JP2015533366A (ja) 2012-10-19 2013-10-21 改良されたヒトヘルペスウイルス免疫療法
JP2018010690A Pending JP2018075034A (ja) 2012-10-19 2018-01-25 改良されたヒトヘルペスウイルス免疫療法
JP2018207238A Active JP6846396B2 (ja) 2012-10-19 2018-11-02 改良されたヒトヘルペスウイルス免疫療法用タンパク質
JP2020185772A Active JP7110302B2 (ja) 2012-10-19 2020-11-06 改良されたヒトヘルペスウイルス免疫療法用タンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018010690A Pending JP2018075034A (ja) 2012-10-19 2018-01-25 改良されたヒトヘルペスウイルス免疫療法
JP2018207238A Active JP6846396B2 (ja) 2012-10-19 2018-11-02 改良されたヒトヘルペスウイルス免疫療法用タンパク質
JP2020185772A Active JP7110302B2 (ja) 2012-10-19 2020-11-06 改良されたヒトヘルペスウイルス免疫療法用タンパク質

Country Status (7)

Country Link
US (4) US9901632B2 (enExample)
EP (3) EP3466980A3 (enExample)
JP (4) JP2015533366A (enExample)
CN (2) CN118359733A (enExample)
AU (2) AU2013332272B2 (enExample)
CA (1) CA2889064A1 (enExample)
WO (1) WO2014059489A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019520840A (ja) * 2016-07-18 2019-07-25 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ マルチウイルス特異的ｔ細胞免疫療法
JP2023526766A (ja) * 2020-04-28 2023-06-23 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ ヒトサイトメガロウイルスポリエピトープワクチン組成物
JP2023549030A (ja) * 2020-10-07 2023-11-22 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ ヘルペスウイルスポリエピトープワクチン

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533366A (ja) 2012-10-19 2015-11-24 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 改良されたヒトヘルペスウイルス免疫療法
WO2016183153A1 (en) * 2015-05-12 2016-11-17 Memorial Sloan Kettering Cancer Center Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
CN105030047A (zh) * 2015-08-31 2015-11-11 捷赛厨电（北京）科技有限公司 可控制油烟的炒锅
BR112020012361A2 (pt) * 2017-12-20 2020-11-24 Glaxosmithkline Biologicals S.A. constructos de antígeno do vírus epstein-barr
US20210393684A1 (en) * 2018-05-18 2021-12-23 The Council Of The Queensland Institute Of Medical Research (Qimr) Adoptive T-Cell Therapy for CMV Infection and CMV-Associated Diseases
EP4458419A3 (en) 2018-09-10 2025-01-08 Atara Biotherapeutics, Inc. Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
US11810904B2 (en) 2020-02-24 2023-11-07 PlayNitride Display Co., Ltd. Micro light emitting diode structure and manufacturing method thereof and micro light emitting diode device
CN111394376B (zh) * 2020-03-30 2023-04-28 济宁医学院 一种融合基因bfna、重组腺病毒及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007689A1 (en) * 2003-07-11 2005-01-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
JP2005504733A (ja) * 2001-06-26 2005-02-17 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ 新規なヒトサイトメガロウイルス（ｈｃｍｖ）細胞傷害性ｔ細胞エピトープ、ポリエピトープ、それを含む組成物、ならびにその診断、予防および治療上の使用
JP2006514606A (ja) * 2002-07-12 2006-05-11 シーエスエル、リミテッド 疎水性タンパク質の発現
WO2006056027A1 (en) * 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
WO2010014567A2 (en) * 2008-08-01 2010-02-04 Merck & Co., Inc. Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
WO2010114628A2 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
JP2010260849A (ja) * 2009-04-30 2010-11-18 Coley Pharmaceutical Group Inc 肺炎球菌ワクチンおよびその使用
JP2012162562A (ja) * 2005-06-30 2012-08-30 Eisai R & D Management Co Ltd 免疫アジュバントの調製のための化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
US6703024B2 (en) * 1996-05-24 2004-03-09 The Council Of The Queensland Institute Of Medical Research EBV CTL epitopes
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US7005131B1 (en) * 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
CA2394748A1 (en) 1999-12-28 2001-07-05 Epimmune Inc. Optimized minigenes and peptides encoded thereby
US7507803B2 (en) 2002-10-03 2009-03-24 Genimmune N.V. Optimized multi-epitope constructs and uses thereof
WO2004041849A1 (en) * 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
BR112013017488A2 (pt) * 2011-01-06 2017-08-01 Bionor Immuno As peptídeos imunogênicos multiméricos e monoméricos
JP2015533366A (ja) 2012-10-19 2015-11-24 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 改良されたヒトヘルペスウイルス免疫療法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504733A (ja) * 2001-06-26 2005-02-17 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ 新規なヒトサイトメガロウイルス（ｈｃｍｖ）細胞傷害性ｔ細胞エピトープ、ポリエピトープ、それを含む組成物、ならびにその診断、予防および治療上の使用
JP2006514606A (ja) * 2002-07-12 2006-05-11 シーエスエル、リミテッド 疎水性タンパク質の発現
WO2005007689A1 (en) * 2003-07-11 2005-01-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
WO2006056027A1 (en) * 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
JP2012162562A (ja) * 2005-06-30 2012-08-30 Eisai R & D Management Co Ltd 免疫アジュバントの調製のための化合物
WO2010014567A2 (en) * 2008-08-01 2010-02-04 Merck & Co., Inc. Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
WO2010114628A2 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
JP2010260849A (ja) * 2009-04-30 2010-11-18 Coley Pharmaceutical Group Inc 肺炎球菌ワクチンおよびその使用

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019520840A (ja) * 2016-07-18 2019-07-25 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ マルチウイルス特異的ｔ細胞免疫療法
JP2022177128A (ja) * 2016-07-18 2022-11-30 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ マルチウイルス特異的ｔ細胞免疫療法
JP2023526766A (ja) * 2020-04-28 2023-06-23 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ ヒトサイトメガロウイルスポリエピトープワクチン組成物
JP2023549030A (ja) * 2020-10-07 2023-11-22 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ ヘルペスウイルスポリエピトープワクチン

Also Published As

Publication number Publication date
JP2021036882A (ja) 2021-03-11
JP7110302B2 (ja) 2022-08-01
US11065329B2 (en) 2021-07-20
AU2013332272A1 (en) 2015-05-14
EP3466980A2 (en) 2019-04-10
US11896665B2 (en) 2024-02-13
EP3466980A3 (en) 2019-05-01
EP2909238A1 (en) 2015-08-26
JP2018075034A (ja) 2018-05-17
AU2018274961A1 (en) 2019-01-03
US20180207261A1 (en) 2018-07-26
US9901632B2 (en) 2018-02-27
US20210299248A1 (en) 2021-09-30
JP6846396B2 (ja) 2021-03-24
CN118359733A (zh) 2024-07-19
EP3872097A1 (en) 2021-09-01
CA2889064A1 (en) 2014-04-24
US20150273051A1 (en) 2015-10-01
WO2014059489A1 (en) 2014-04-24
US20240156953A1 (en) 2024-05-16
EP2909238A4 (en) 2016-11-30
AU2013332272B2 (en) 2018-12-20
JP2019030331A (ja) 2019-02-28
CN104918960B (zh) 2024-06-14
CN104918960A (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
JP7110302B2 (ja) 改良されたヒトヘルペスウイルス免疫療法用タンパク質
AU2006200654C1 (en) Inducing cellular immune responses to human papilloma virus using peptide and nucleic acid compositions
US20070014810A1 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US10350284B1 (en) Antigen specific multi epitope-based anti-infective vaccines
US20070048329A1 (en) Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
Liu et al. Immunotherapy of Epstein-Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356–364 epitope fusion protein
Beverley et al. Strategies for studying mouse and human immune responses to human papillomavirus type 16
HK40057947A (en) Improved human herpesvirus immunotherapy
HK40006634A (en) Improved human herpesvirus immunotherapy
WO2024219974A1 (en) Timp3-derived teipp neoantigens and uses thereof
AU2024257340A1 (en) Rcn1-derived teipp neoantigens and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180703